Hansa Medical postpones Annual General Meeting

Hansa Medical AB (publ) announces that it´s Annual General Meeting is scheduled
to be held May 11, 2016.
The company has previously announced that its Annual General Meeting was to be
held April 27, 2016. The board of directors has resolved that the general
meeting be postponed to be held May 11, 2016. The reason for the postponement is
that the nomination committee needs more time for discussion with the company’s
large shareholders due to the changes in ownership, which occurred on March 8,
2016.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: +46 70 633 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory
enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical
development, with potential use in transplantation and rare autoimmune diseases.
Additional projects focus on development of new antibody modulating enzymes, as
well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency
departments that is already introduced on the market. The company is based in
Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq
Stockholm.